A5070999281- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Rheumatoid Arthritis Research and Therapies
- Hepatocellular Carcinoma Treatment and Prognosis
- HER2/EGFR in Cancer Research
- Inhalation and Respiratory Drug Delivery
- Systemic Lupus Erythematosus Research
- Lung Cancer Treatments and Mutations
- Vasculitis and related conditions
- Cell Adhesion Molecules Research
- Gastric Cancer Management and Outcomes
- Immunodeficiency and Autoimmune Disorders
- Pharmacogenetics and Drug Metabolism
- Protein purification and stability
- Autism Spectrum Disorder Research
- Complement system in diseases
- Cancer Immunotherapy and Biomarkers
- Vascular Anomalies and Treatments
- Lung Cancer Research Studies
- Renal Transplantation Outcomes and Treatments
- Colorectal and Anal Carcinomas
- Tracheal and airway disorders
- Child Development and Digital Technology
Université de Tours
2014-2024
Physiologie de la Reproduction et des Comportements
2023-2024
Centre National de la Recherche Scientifique
2011-2023
Centre Hospitalier Universitaire de Tours
2008-2020
Centre Val de Loire
2013
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2011
Centre de Biophysique Moléculaire
2011
Inserm
2011
Canadian Nautical Research Society
2009
Cetuximab is an anti-epidermal growth factor receptor monoclonal antibody used in the treatment of colorectal and head neck cancers. Part interindividual differences response may be explained by variability pharmacokinetics. An assay measuring cetuximab serum concentrations therefore needed. enzyme-linked immunosorbent was developed using microtiter plates sensitized with a recombinant human epidermal extracellular domain. Lower upper limits quantitation limit detection were determined....
Abstract Purpose: An ancillary phase II study was conducted to interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) metastatic colorectal cancer patients cotreated with irinotecan 5-fluorouracil. Experimental Design: Ninety-six received as an infusion loading dose of 400 mg/m2 followed by weekly infusions 250 mg/m2. Doses 5-fluorouracil were adjusted individually. Cetuximab concentrations measured ELISA. Compartmental pharmacokinetic...
Bevacizumab-a humanized monoclonal antibody-has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet conducted.This study is a double-blind multicenter phase 2 1:1 active-treatment-to-placebo ratio. We included over the age of 18 confirmed diagnosis and need for at least four red blood cell (RBC) units transfused in 3 months before enrollment. Bevacizumab was administered dose 5 mg/kg every 14 days total six injections. The...
The neonatal Fc receptor (FcRn) encoded by FCGRT is known to be involved in the pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs). Variability expression gene and consequently FcRn protein level could explain differences PK observed between patients treated with mAbs. We studied whether previously described variable number tandem repeat (VNTR) or copy variation (CNV) are associated individual variations parameters cetuximab. VNTR CNV were assessed on genomic DNA 198 healthy...
<title>Abstract</title> Autism spectrum disorders (ASD) are complex, polygenic and heterogenous neurodevelopmental conditions, imposing a substantial economic burden. ASD genetics is influenced by the environment, specifically social experience during critical period. Despite efficacy of early behavioral interventions targeting specific behaviors in some autistic children, there currently no sustainable treatment for two core symptoms: deficits interaction communication, stereotyped or...
K-ras mutations promote angiogenesis in lung cancer and contribute to the drug resistance of cells. It is not clear whether mutated adenocarcinomas are sensitive anti-angiogenic therapy with monoclonal antibodies (mAbs) that target vascular endothelial growth factor (VEGF). Anti-angiogenic mAbs usually delivered systemically, but only a small proportion reaches after intravenous injection. We investigated relevance non-invasive pulmonary route for delivery anti-VEGF mouse K-ras(LA1) model....
Hereditary hemorrhagic telangiectasia (HHT), a genetic vascular disorder associated with epistaxis and hepatic shunts, is responsible for high-output cardiac failure in rare cases. Bevacizumab, which targets endothelial growth factor, was shown to decrease both index (CI) duration HHT patients severe liver involvement. The relationship between its serum concentration change CI investigated design the bevacizumab maintenance dosing regimen of future therapeutic studies. Twenty-five dyspnea...
A retrospective study was conducted to analyze interindividual variability of cetuximab pharmacokinetics and its influence on survival (progression-free overall [OS]) in a cohort head neck squamous cell carcinoma (HNSCC).Thirty-four patients received as an infusion loading dose 400 mg/m followed by weekly infusions 250 mg/m. Twenty-one had locally advanced HNSCC, 13 metastatic/recurrent HNSCC. Cetuximab concentrations were measured the enzyme-linked immunosorbent assay, analyzed population...
Objective To identify patient characteristics associated with responsiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). Materials and methods Individual data from 29 randomised controlled trials (RCTs) evaluating the efficacy of a TNFi versus placebo or conventional therapy were obtained. Response treatment was assessed subgroups according following baseline characteristics: smoking status, physical activity, sex, age, body mass index, autoantibody profile,...
An ancillary phase II study was conducted to interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) metastatic colorectal cancer patients cotreated with irinotecan 5-fluorouracil.Ninety-six received as an infusion loading dose of 400 mg/m(2) followed by weekly infusions 250 mg/m(2). Doses 5-fluorouracil were adjusted individually. Cetuximab concentrations measured ELISA. Compartmental pharmacokinetic parameters estimated a population...
Abstract The immunogenicity of infliximab and adalimumab is a major concern because patients may develop Abs also called antidrug (ADA), directed against these anti–TNF-α after just few weeks treatment. These ADAs can lead to decrease in biologic concentration, which associated with lower treatment efficacy. Our aim was study the involvement immune complexes neonatal Fc receptor (FcRn) emergence case Abs. Wild type FcRn knockout mice were injected once either or adalimumab, alone...
Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease CD4+ count was observed responders after a single cycle of treatment. This study aimed to describe and quantifying the influence depletion on concentration-response relationship rituximab RA patients.In this retrospective monocentric observational study, 52 patients were assessed. Repeated measurements concentrations (pharmacokinetics), counts (biomarker) disease activity score 28 joints (DAS28, clinical response)...
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect papulopustular acneiform rash. The aim the CUTACETUX study was to characterize skin inflammatory response associated with this rash relation efficacy.This prospective included patients mCRC treated first-line chemotherapy plus cetuximab. Patients underwent biopsies before initiation cetuximab (D0) third infusion (D28), one in zone...
Autism spectrum disorders (ASD) are complex, polygenic and heterogenous neurodevelopmental conditions. The severity of autism-associated variants is influenced by environmental factors, particularly social experiences during the critical period. While early behavioral interventions have shown efficacy in some children with autism, pharmacological support for core features — impairments interaction communication, stereotyped or restricted behaviors currently lacking. In this study, we...